A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma.

Christopher W Ryan,M Eileen Dolan,Bruce B Brockstein,Roger McLendon,Shannon M Delaney,Brian L Samuels, Edem S Agamah,Everett E Vokes

Cancer chemotherapy and pharmacology（2006）

Cited 36|Views35

No score

Abstract

Observed toxicities were consistent with previous studies of O6-BG plus BCNU. The degree of MGMT expression was variable in this small sample of heterogeneous sarcomas. Further development of this regimen and dose for the treatment of soft tissue sarcoma is not warranted due to the lack of objective responses.

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined